Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 10, 2003

View Archived Issues

Protein Design Labs set out new initiatives for 2003

ViroPharma updates product pipeline

Axokine granted fast track designation for severe obesity

CA4P enters new phase I/II trial in advanced cancers

Campath compared to Rebif in phase II MS study

BioBypass-PAD fails to meet phase II clinical endpoints in peripheral arterial disease

Roche presents novel alpha5-selective GABA-A receptor modulators

Novel cytokine inhibitors discovered by Procter & Gamble researchers

Lilly claims 5-HT and noradrenaline reuptake inhibitors for pain and other uses

New MCH receptor modulators in early development at Neurogen

GSK scientists identify new B-Raf kinase inhibitors

Peptide CCK modulators and their use in the diagnosis and treatment of cancer

Successful conclusion of phase I trial of ZP-120

Celgene summarizes recent clinical development highlights

Patient treatment under way in phase II trial of DCF-987 for cystic fibrosis

DX-88 granted E.U. orphan drug status for acquired and hereditary angioedema

BioSante and Teva to develop hormone therapy product

Aphios awarded SBIR grant for development of novel antiinfluenza agents

Medarex and Ability Biomedical to develop fully human antibody therapeutics

NitroMed and Merck & Co. form NO-based medicines development collaboration

DOR BioPharma executes option for nontoxic ricin vaccine technology

Boehringer Ingelheim and Sagres form oncology collaboration

Promising results obtained with anidulafungin in invasive candidiasis/candidemia

Potential use of candesartan cilexetil in migraine prophylaxis

Sildenafil reported effective in preventing antidepressant-associated sexual dysfunction

Antitumor activity reported for BioVex's OncoVEX(GM-CSF)

A potential new indication proposed for losartan

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...